ArticleJACC. Asia2026
Procedural Pattern, Clinical Outcomes, and Cost Analysis of Transcatheter Aortic Valve Replacement in Korea.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle information exists about national-based data on patients undergoing transcatheter aortic valve replacement (TAVR) in Asia and the associated costs.
objectivesThis study aims to assess the baseline characteristics, procedural patterns, clinical outcomes, and cost expenses of patients with severe aortic stenosis who underwent TAVR in Korea.
methodsWe used the patient-level data from the National Health Insurance Review and Assessment Service registry, spanning from May 2015 to June 2021. The primary clinical outcome was all-cause mortality. Rehospitalization rates and procedural costs were also analyzed.
resultsDuring the study period, 3,463 patients (mean age: 80.5 ± 5.9 years; 54.0% female) underwent TAVR at 39 hospitals in Korea. The annual number of TAVR procedures and the number of performing centers increased steadily. The proportion of low-risk patients (Society of Thoracic Surgeons Predicted Risk of Mortality ≤4%) was 41.7%. The transfemoral approach was conducted in 99.0% of cases, and the procedural success rate was 99.7%. All-cause mortality rates at 30 days, 2 years, and 5 years were 2.7% (95% CI: 2.1-3.2), 12.9% (95% CI: 11.8-14.0), and 19.5% (95% CI: 18.0-21.1), respectively. Rehospitalization related to cardiovascular causes occurred in 31.7% (95% CI: 29.3-34.1) at 2 years and 40.5% (95% CI: 34.1-46.9) at 5 years. The estimated mean index cost per patient was $32,173 ± $7,552, with 83.2% attributed to material expenses.
conclusionsThe number of TAVR recipients and performing centers in Korea has substantially increased over time. The procedural and survival outcomes were favorable. The overall medical costs for TAVR procedures are still substantial, mainly driven by device costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.